Last reviewed 2026-05-28 · How we verify

Hesperitin (Hesperetin)

University of Vienna · Phase 1 active Small molecule ✓ Verified May 2026

Hesperitin (generic name: Hesperetin) is a hesperetin Small molecule drug developed by University of Vienna. It is currently in Phase 1 development. Also known as: (2S)-3',5,7-Trihydroxy-4'-methoxyflavan-4-one, CAS number 520-33-2.

Hesperitin works by blocking the enzyme carbonic anhydrase 7, which helps regulate the balance of fluids and electrolytes in the body.

Hesperetin is a small molecule flavanone that is a derivative of eriodictyol, with hesperidin being its 7-O-glycoside form found naturally in citrus fruits. Hesperetin has been studied in clinical trials for its potential ergogenic properties, including reducing exercise-induced fatigue and blood glucose fluctuations, as well as its effects on hunger and glucose intolerance.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Hesperetin
Also known as	(2S)-3',5,7-Trihydroxy-4'-methoxyflavan-4-one, CAS number 520-33-2
Sponsor	University of Vienna
Drug class	hesperetin
Target	Cytochrome P450 1B1, Lysine-specific histone demethylase 1A, Carbonic anhydrase 12
Modality	Small molecule
Therapeutic area	Metabolic
Phase	Phase 1

Mechanism of action

Think of carbonic anhydrase 7 like a pump that helps move fluids and electrolytes in and out of cells. When Hesperitin blocks this pump, it can help regulate the balance of fluids and electrolytes in the body, which can be beneficial for people with certain medical conditions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluation of the Ergogenic Properties of Hesperetin on Exercise-induced Fatigue (NA)
Impact Hesperetin in Combination with Sucrose on Blood Glucose Regulation (EARLY_PHASE1)
Impact of Hesperetin in Combination With Sucrose on Energy Metabolism (EARLY_PHASE1)
Healthy Aging Through Functional Food (PHASE1,PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Hesperitin CI brief — competitive landscape report
Hesperitin updates RSS · CI watch RSS
University of Vienna portfolio CI

Frequently asked questions about Hesperitin

What is Hesperitin?

Hesperitin (Hesperetin) is a hesperetin drug developed by University of Vienna.

How does Hesperitin work?

Hesperitin works by blocking the enzyme carbonic anhydrase 7, which helps regulate the balance of fluids and electrolytes in the body.

Who makes Hesperitin?

Hesperitin is developed by University of Vienna (see full University of Vienna pipeline at /company/university-of-vienna).

What is the generic name of Hesperitin?

Hesperetin is the generic (nonproprietary) name of Hesperitin.

Is Hesperitin also known as anything else?

Hesperitin is also known as (2S)-3',5,7-Trihydroxy-4'-methoxyflavan-4-one, CAS number 520-33-2.

What drug class is Hesperitin in?

Hesperitin belongs to the hesperetin class. See all hesperetin drugs at /class/hesperetin.

What development phase is Hesperitin in?

Hesperitin is in Phase 1.

What does Hesperitin target?

Hesperitin targets Cytochrome P450 1B1, Lysine-specific histone demethylase 1A, Carbonic anhydrase 12 and is a hesperetin.

Drug class: All hesperetin drugs
Target: All drugs targeting Cytochrome P450 1B1, Lysine-specific histone demethylase 1A, Carbonic anhydrase 12
Manufacturer: University of Vienna — full pipeline
Therapeutic area: All drugs in Metabolic
Also known as: (2S)-3',5,7-Trihydroxy-4'-methoxyflavan-4-one, CAS number 520-33-2

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing